These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 30528119)

  • 1. Systemic Administered mRNA as Therapy for Metabolic Diseases.
    Puy H; Deybach JC; Gouya L
    Trends Mol Med; 2019 Jan; 25(1):3-5. PubMed ID: 30528119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria.
    Jiang L; Berraondo P; Jericó D; Guey LT; Sampedro A; Frassetto A; Benenato KE; Burke K; Santamaría E; Alegre M; Pejenaute Á; Kalariya M; Butcher W; Park JS; Zhu X; Sabnis S; Kumarasinghe ES; Salerno T; Kenney M; Lukacs CM; Ávila MA; Martini PGV; Fontanellas A
    Nat Med; 2018 Dec; 24(12):1899-1909. PubMed ID: 30297912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria.
    Johansson A; Nowak G; Möller C; Blomberg P; Harper P
    Mol Ther; 2004 Aug; 10(2):337-43. PubMed ID: 15294180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria.
    Johansson A; Nowak G; Möller C; Harper P
    Mol Genet Metab; 2004 May; 82(1):20-6. PubMed ID: 15110317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice.
    Unzu C; Sampedro A; Mauleón I; González-Aparicio M; Enríquez de Salamanca R; Prieto J; Aragón T; Fontanellas A
    Hum Mol Genet; 2013 Jul; 22(14):2929-40. PubMed ID: 23562909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Era for Rare Genetic Diseases: Messenger RNA Therapy.
    Martini PGV; Guey LT
    Hum Gene Ther; 2019 Oct; 30(10):1180-1189. PubMed ID: 31179759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria.
    Pañeda A; Lopez-Franco E; Kaeppel C; Unzu C; Gil-Royo AG; D'Avola D; Beattie SG; Olagüe C; Ferrero R; Sampedro A; Mauleon I; Hermening S; Salmon F; Benito A; Gavira JJ; Cornet ME; del Mar Municio M; von Kalle C; Petry H; Prieto J; Schmidt M; Fontanellas A; González-Aseguinolaza G
    Hum Gene Ther; 2013 Dec; 24(12):1007-17. PubMed ID: 24070415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria.
    Yin Z; Wahlin S; Ellis EC; Harper P; Ericzon BG; Nowak G
    Cell Transplant; 2014; 23(9):1153-62. PubMed ID: 23582197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
    Unzu C; Sampedro A; Mauleón I; Vanrell L; Dubrot J; de Salamanca RE; González-Aseguinolaza G; Melero I; Prieto J; Fontanellas A
    J Hepatol; 2010 Mar; 52(3):417-24. PubMed ID: 19815305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria.
    Serrano-Mendioroz I; Sampedro A; Alegre M; Enríquez de Salamanca R; Berraondo P; Fontanellas A
    Hum Gene Ther; 2018 Apr; 29(4):480-491. PubMed ID: 28990424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies.
    Parra-Guillen ZP; Fontanellas A; Jiang L; Jericó D; Martini P; Vera-Yunca D; Hard M; Guey LT; Troconiz IF
    Br J Pharmacol; 2020 Jul; 177(14):3168-3182. PubMed ID: 32133631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria.
    Serrano-Mendioroz I; Sampedro A; Mora MI; Mauleón I; Segura V; Enríquez de Salamanca R; Harper P; Sardh E; Corrales FJ; Fontanellas A
    J Proteomics; 2015 Sep; 127(Pt B):377-85. PubMed ID: 25979770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency.
    Collantes M; Serrano-Mendioroz I; Benito M; Molinet-Dronda F; Delgado M; Vinaixa M; Sampedro A; Enríquez de Salamanca R; Prieto E; Pozo MA; Peñuelas I; Corrales FJ; Barajas M; Fontanellas A
    Hum Mol Genet; 2016 Apr; 25(7):1318-27. PubMed ID: 26908609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmenting PBGD expression in the liver as a novel gene therapy for acute intermittent porphyria (AIPgene).
    Hum Gene Ther Clin Dev; 2014 Jun; 25(2):61-3. PubMed ID: 24933563
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
    Sardh E; Rejkjaer L; Andersson DE; Harper P
    Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasomal degradation regulates expression of porphobilinogen deaminase (PBGD) mutants of acute intermittent porphyria.
    Grünberg-Etkovitz N; Greenbaum L; Grinblat B; Malik Z
    Biochim Biophys Acta; 2006 Sep; 1762(9):819-27. PubMed ID: 16935474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Three new mutations in the porphobilinogen deaminase gene, detected in acute intermittent porphyria patients from Russia].
    Surin VL; Luk'ianenko AV; Karpova IV; Misiurin AV; Pustovot IaS; Pivnik AV
    Genetika; 2001 May; 37(5):690-7. PubMed ID: 11436563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria.
    Serrano-Mendioroz I; Sampedro A; Serna N; de Salamanca RE; Sanz-Parra A; Corrales F; Berraondo P; Millet O; Fontanellas A
    Hum Mol Genet; 2018 Nov; 27(21):3688-3696. PubMed ID: 30085095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Porphobilinogen deaminase gene mutations in Polish patients with non-erythroid acute intermittent porphyria.
    Szlendak U; Lipniacka A; Bianketti J; Podolak-Dawidziak M; Bykowska K
    Adv Clin Exp Med; 2015; 24(1):63-8. PubMed ID: 25923088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute intermittent porphyria.
    Grandchamp B
    Semin Liver Dis; 1998; 18(1):17-24. PubMed ID: 9516674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.